{"title":"抗癌药物组合，从不同途径的研究","authors":"D. Lu","doi":"10.4172/2168-9296.1000166","DOIUrl":null,"url":null,"abstract":"Most cancer therapies are seldom effective by single anticancer drug based on multiple genetic alterations and molecular abnormalities. Anticancer drug combination utilities need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapies by mathematical enquiry. Possible future landscapes and drawbacks of current cancer drug combinative therapy are addressed and speculated.","PeriodicalId":9775,"journal":{"name":"Cell & developmental biology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":"{\"title\":\"Anticancer Drug Combinations, Studies from Different Pathways\",\"authors\":\"D. Lu\",\"doi\":\"10.4172/2168-9296.1000166\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Most cancer therapies are seldom effective by single anticancer drug based on multiple genetic alterations and molecular abnormalities. Anticancer drug combination utilities need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapies by mathematical enquiry. Possible future landscapes and drawbacks of current cancer drug combinative therapy are addressed and speculated.\",\"PeriodicalId\":9775,\"journal\":{\"name\":\"Cell & developmental biology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell & developmental biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2168-9296.1000166\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell & developmental biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2168-9296.1000166","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Anticancer Drug Combinations, Studies from Different Pathways
Most cancer therapies are seldom effective by single anticancer drug based on multiple genetic alterations and molecular abnormalities. Anticancer drug combination utilities need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapies by mathematical enquiry. Possible future landscapes and drawbacks of current cancer drug combinative therapy are addressed and speculated.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
